OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Key Points

• Citizens Jmp raised OptimizeRx’s price target from $9 to $11 and maintained a “market outperform” rating, implying 25.28% upside from the prior close.
• Analyst sentiment is generally positive but mixed: six analysts rate the stock a Buy, two a Hold and one a Sell, resulting in a “Moderate Buy” consensus and an average target price of $11.43.
• OptimizeRx exceeded quarterly expectations, reporting $0.16 in earnings per share versus the $0.11 consensus and revenue of $20.50 million versus $20.20 million expected; institutional investors own 76.47% of the company.

OptimizeRx (NASDAQ:OPRX - Get Free Report) had its target price increased by investment analysts at Citizens Jmp from $9.00 to $11.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a "market outperform" rating on the stock. Citizens Jmp's price objective points to a potential upside of 25.28% from the company's previous close.

Other analysts have also issued reports about the company. Citigroup reaffirmed a "market outperform" rating on shares of OptimizeRx in a research report on Friday. Weiss Ratings restated a "sell (d)" rating on shares of OptimizeRx in a research note on Tuesday. B. Riley Financial cut their target price on OptimizeRx from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 13th. Zacks Research cut OptimizeRx from a "strong-buy" rating to a "hold" rating in a research note on Monday, May 4th. Finally, Lake Street Capital decreased their price target on shares of OptimizeRx from $20.00 to $11.00 and set a "buy" rating for the company in a research report on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $11.43.

OptimizeRx Price Performance

OPRX opened at $8.78 on Friday. OptimizeRx has a 52-week low of $4.54 and a 52-week high of $22.25. The company has a 50 day moving average of $6.04 and a two-hundred day moving average of $6.72. The company has a market cap of $164.71 million, a P/E ratio of 38.18 and a beta of 1.08. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. The company had revenue of $20.50 million for the quarter, compared to analysts' expectations of $20.20 million. OptimizeRx had a return on equity of 9.52% and a net margin of 4.66%. On average, analysts expect that OptimizeRx will post 0.51 earnings per share for the current year.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds have recently made changes to their positions in OPRX. Next Century Growth Investors LLC lifted its holdings in OptimizeRx by 139.8% in the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company's stock worth $6,196,000 after purchasing an additional 294,688 shares during the period. Manatuck Hill Partners LLC raised its position in shares of OptimizeRx by 139.5% during the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company's stock worth $6,142,000 after buying an additional 265,000 shares in the last quarter. Kennedy Capital Management LLC lifted its stake in shares of OptimizeRx by 42.8% in the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company's stock worth $13,836,000 after acquiring an additional 202,446 shares during the period. Invesco Ltd. acquired a new stake in shares of OptimizeRx in the 3rd quarter worth approximately $4,081,000. Finally, Segall Bryant & Hamill LLC bought a new position in shares of OptimizeRx in the first quarter valued at approximately $1,185,000. Institutional investors own 76.47% of the company's stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company's core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source